Advertisement

Topics

Astellas Pharma GmbH Company Profile

15:28 EDT 22nd September 2018 | BioPortfolio

Aktuelle Studie belegt: Fluvastatin senkt die Blutfette sicher und effektiv unabhängig von der Tageszeit Dresden, 6. Oktober 2005. Die Retard-Formulierung von Fluvastatin wirkt effektiv und sicher, auch unabhängig vom Zeitpunkt der Einnahme. Das Präparat ermöglicht eine optimale Blutfetteinstellung über 24 Stunden, ganz gleich, zu welchem Zeitpunkt des Tages - morgens oder abends - das Medikament eingenommen wird. Dies fördert die Compliance, da der Zeitpunkt der Tabletteneinnahme individuell an den jeweiligen Patienten angepasst werden kann. Ein Vorteil für den Arzt und den Patienten. Zu diesem Ergebnis kommt eine neue Studie des Klinischen Instituts für Medizinische und Chemische Labordiagnostik der Universität Graz, die erstmals am 6. Oktober auf der Herbsttagung der Kardiologen in Dresden präsentiert wurde

Location

Postfach 80 06 28
Munich
München
D-81606
Germany

Contact

Phone: (089) 45 44 - 01
Fax: (089) 45 44 - 13 29
Email: info@de.astellas.com


News Articles [913 Associated News Articles listed on BioPortfolio]

Astellas Pharma Acquires Quethera

NewsThrough this transaction, Astellas has acquired Quethera's ophthalmic gene therapy program.

Astellas Pharma acquires Quethera for $108.5m

Japan-based Astellas Pharma has acquired British gene therapy company Quethera, which primarily develops new treatments for ocular diseases such as...Read More... The post Astellas Pharma acquires Que...

Astellas gibt Übernahme von Quethera bekannt

Übernahme fördert das Engagement von Astellas für Innovationen in der Augenheilkunde mit neuartigem Gentherapieprogramm für Glaukom Tokyo und Cambridge, England (ots/PRNewswire) - Astellas Pharma ...

FDA Approves Pfizer And Astellas Pharma's Xtandi

NewsThis approval makes Xtandi the first and only oral medication FDA-approved for both non-metastatic and metastatic castration-resistant prostate cancer (CRPC).

FDA priority review status granted to Astellas' AML drug

Astellas Pharma's gilteritinib, which is being developed as a treatment for adult patients with relapsed/refractory FLT3-posi -More- 

Astellas wins expanded label to include pediatric use for oral solifenacin

Tokyo-based Astellas Pharma has been awarded EU approval for its neurogenic detrusor overactivity (NDO)…

Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

TOKYO and BOTHELL, Wash., March 26, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced t...

Astellas reports on late-stage trial for chronic kidney disease drug

Astellas Pharma announced that the key endpoints were met for its Phase III study to evaluate its candidate roxadustat as a t -More- 

Drugs and Medications [277 Associated Drugs and Medications listed on BioPortfolio]

Vesicare [Astellas Pharma Technologies, Inc.]

These highlights do not include all the information needed to use VESIcare safely and effectively. See full prescribing information for VESIcare. VESIcare (solifenacin succinate) tablets Initial U.S. ...

Alcohol prep pad [Büttner-Frank GmbH]

La prairie switzerland [Juvena Produits de Beaute GMBH]

Package.Label Principle Display Panel

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 1 mg

PubMed Articles [31 Associated PubMed Articles listed on BioPortfolio]

Cost-effectiveness analysis of blue light cystoscopy with hexylaminolevulinate in transurethral resection of the bladder.

Photodynamic diagnosis using the optical imaging agent hexaminolevulinate (HAL, Hexvix®, Ipsen Pharma GmbH, Ettlingen, Germany) as an adjunct to white light cystoscopy (WLC) during the initial transu...

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Clinical trials go virtual, big pharma dives in.

Correction to: Lonoctocog Alfa: A Review in Haemophilia A.

The article Lonoctocog Alfa: A Review in Haemophilia A, written by Zaina T. Al-Salama and Lesley J. Scott, was originally published Online First without open access. After publication in volume 77...

21 Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Perpetual debate regarding the delicate balance between access and innovation and the protection of the public health and safety dominate discussions of the United States Food and Drug Administration ...

Clinical Trials [125 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (L...

Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

The primary objective is to determine clinical bioequivalence of Amphotericin B liposome for injection of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) liposome for injection of...

Bioequivalence Study of Tacrolimus 5 mg Capsule Under Fed Condition

The objective of the study is to demonstrate bioequivalence between Test Product (A): Tacrolimus Capsules 5 mg, manufactured by Panacea Biotec Limited, India and the corresponding Referenc...

Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fed Condition

The objective of the study is to demonstrate bioequivalence between Test Product (A): Tacrolimus Capsules 1 mg, manufactured by Panacea Biotec Limited, India and the corresponding Referenc...

Companies [1272 Associated Companies listed on BioPortfolio]

Astellas Pharma Canada, Inc.

Astellas Pharma Europe Ltd., located in the UK, is the European Headquarters of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the he...

Astellas Pharma Global Development

Astellas Pharma Global Development, located in Deerfield, Illinois, is a group company of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of peo...

Astellas Pharma Inc.

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals...

Astellas Pharma Europe Ltd.

Astellas Pharma Europe Ltd., located in the UK, is a European subsidiary of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around...

Potenza Therapeutics, Inc.

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and rel...

More Information about "Astellas Pharma GmbH" on BioPortfolio

We have published hundreds of Astellas Pharma GmbH news stories on BioPortfolio along with dozens of Astellas Pharma GmbH Clinical Trials and PubMed Articles about Astellas Pharma GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Astellas Pharma GmbH Companies in our database. You can also find out about relevant Astellas Pharma GmbH Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record